Preclinical biomarkers in Alzheimer disease a sum greater than the parts

JAMA Neurology

Volumn 71, Issue 11, 2014, Pages 1357-1358

  Resnick, Susan M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; BRAIN SIZE; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EDITORIAL; EVALUATION STUDY; FOLLOW UP; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; NERVE DEGENERATION; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; COGNITION DISORDERS; FEMALE; MALE; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MALE;

EID: 84919330565     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2462     Document Type: Editorial

References (10)

1. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs213. doi:10.1126/scitranslmed.3007941.
2. Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals [published online September 15, 2014]. JAMA Neurol. doi:10.1001/jamaneurol.2014.2031.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
4. Jack CR Jr, Knopman DS,Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71 (6):765-775.
5. Jack CR Jr, Knopman DS, JagustWJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
6. Jack CR Jr, Knopman DS, JagustWJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-216.
7. Jack CR Jr,Wiste HJ,Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732-1740.
8. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore Longitudinal Study of Aging. Ann Neurol. 2008;64(2):168-176.
9. Schneider JA,Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62(7):1148-1155.
10. Bilgel M, An Y, Lang A, et al. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. Alzheimers Dement. 2014.